Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the p300/CBP Axis in Lethal Prostate Cancer

11 Jan 2021

Abstract excerpt

Abstract Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR activity, including the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal prostate cancer. Herein, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33431496
DOI: 10.1158/2159-8290.cd-20-0751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the p300/CBP Axis in Lethal Prostate CancerPMID 33431496Read ↗

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSemantic proximity Read ↗

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSemantic proximity Read ↗

Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell LinesSemantic proximity Read ↗

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancerSemantic proximity Read ↗

YY1 relieves p300 autoinhibition to promote histone acetylation in advanced prostate cancer, enhancing the oncogenic signaling of Androgen Receptor Splice Variant 7Semantic proximity Read ↗

EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cellsSemantic proximity Read ↗

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerSemantic proximity Read ↗

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular CarcinomaSemantic proximity Read ↗

Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatmentSemantic proximity Read ↗

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.Semantic proximity Read ↗

The long noncoding RNA HORAS 5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional programSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.